D. Boral Capital Maintains Buy on Immunic, Maintains $8 Price Target

Benzinga · 01/07 13:57
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $8 price target.